Real‐Life Perception of Treatment Effectiveness After 24 Weeks of Topical Ruxolitinib in Non‐Segmental Vitiligo: Insights From Patient‐Reported Outcomes
Silvia Alberti‐Violetti(University of Milan), Angelo Valerio Marzano(University of Milan), Gianluca Tavoletti(University of Milan), Luisa Rossi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Emanuele Cozzani(Ospedale Policlinico San Martino), Francesca Del Signore(University of Milan), Niccolò Capurro(University of Genoa), Maurizio Romagnuolo(University of Siena)
Cited by 1
Related Papers
Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
|Journal of Clinical Medicine|2022|31
Guselkumab‐associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature
|Dermatologic Therapy|2021|21
A deep learning approach to direct immunofluorescence pattern recognition in autoimmune bullous diseases
|British Journal of Dermatology|2024|17
Self‐resolving bullous pemphigoid induced by cemiplimab
|Dermatologic Therapy|2022|6